Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2013 Financial Results
— Webcast of presentation at upcoming investor conference also announced — WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate technology, today announced
View HTML
Toggle Summary ImmunoGen, Inc. Announces FDA Acceptance of IND for Company's Novel EGFR-Targeting ADC, IMGN289
Novel antibody-drug conjugate (ADC) IMGN289 on track to begin human clinical testing for treatment of EGFR-positive tumors in 4Q2013. IMGN289 is a potential new treatment for lung, head and neck, and other EGFR-positive solid tumors, including ones not effectively treated with EGFR-directed
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
Kadcyla ® sales off to strong start. Decision on approval in European Union , TH3RESA Phase III data presentation expected by Roche in 2H2013. ImmunoGen progress with its proprietary pipeline includes advancement of third wholly owned product candidate for solid tumors, IMGN289, to active IND and
View HTML
Toggle Summary ImmunoGen, Inc. Announces Executive Change
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Gregory D. Perry , Executive Vice President and Chief Financial Officer, has
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor
View HTML
Toggle Summary ImmunoGen, Inc. Announces Positive Regulatory Decisions for Roche's Kadcyla® in the European Union and Japan
CHMP has issued a positive opinion for Kadcyla, with the European Commission decision expected by the end of 2013. The Japanese MHLW has approved Kadcyla for marketing in Japan , which triggers a $5 million milestone payment to ImmunoGen. Kadcyla comprises Roche's trastuzumab antibody and
View HTML
Toggle Summary ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress
Roche's Kadcyla found to significantly extend duration of progression-free survival in patients with advanced HER2-positive breast cancer in second large randomized trial. Kadcyla comprises Roche's trastuzumab antibody and ImmunoGen's ADC technology; it has been approved for marketing in several
View HTML
Toggle Summary ImmunoGen, Inc. Announces New License Agreement
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop
View HTML
Toggle Summary ImmunoGen, Inc. Announces Presentations at Upcoming AACR-NCI-EORTC Anticancer Conference
First clinical data to be reported for SAR566658 , further expanding the extensive body of data reported with ImmunoGen's maytansinoid antibody-drug conjugate (ADC) technology. Presentations on new ADC technologies, including a new class of payload agents, highlight ImmunoGen's continuing
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2014 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML